244 related articles for article (PubMed ID: 22402037)
1. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.
La Rosa C; Longmate J; Lacey SF; Kaltcheva T; Sharan R; Marsano D; Kwon P; Drake J; Williams B; Denison S; Broyer S; Couture L; Nakamura R; Dadwal S; Kelsey MI; Krieg AM; Diamond DJ; Zaia JA
J Infect Dis; 2012 Apr; 205(8):1294-304. PubMed ID: 22402037
[TBL] [Abstract][Full Text] [Related]
2. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.
Nakamura R; La Rosa C; Longmate J; Drake J; Slape C; Zhou Q; Lampa MG; O'Donnell M; Cai JL; Farol L; Salhotra A; Snyder DS; Aldoss I; Forman SJ; Miller JS; Zaia JA; Diamond DJ
Lancet Haematol; 2016 Feb; 3(2):e87-98. PubMed ID: 26853648
[TBL] [Abstract][Full Text] [Related]
3. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.
La Rosa C; Wang Z; Brewer JC; Lacey SF; Villacres MC; Sharan R; Krishnan R; Crooks M; Markel S; Maas R; Diamond DJ
Blood; 2002 Nov; 100(10):3681-9. PubMed ID: 12393676
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
[TBL] [Abstract][Full Text] [Related]
5. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
6. Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.
Van Craenenbroeck AH; Smits EL; Anguille S; Van de Velde A; Stein B; Braeckman T; Van Camp K; Nijs G; Ieven M; Goossens H; Berneman ZN; Van Tendeloo VF; Verpooten GA; Van Damme P; Cools N
Transplantation; 2015 Jan; 99(1):120-7. PubMed ID: 25050468
[TBL] [Abstract][Full Text] [Related]
7. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Adler SP
J Clin Virol; 2006 Mar; 35(3):332-7. PubMed ID: 16387547
[TBL] [Abstract][Full Text] [Related]
8. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.
La Rosa C; Longmate J; Martinez J; Zhou Q; Kaltcheva TI; Tsai W; Drake J; Carroll M; Wussow F; Chiuppesi F; Hardwick N; Dadwal S; Aldoss I; Nakamura R; Zaia JA; Diamond DJ
Blood; 2017 Jan; 129(1):114-125. PubMed ID: 27760761
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection.
Gergely KM; Podlech J; Becker S; Freitag K; Krauter S; Büscher N; Holtappels R; Plachter B; Reddehase MJ; Lemmermann NAW
Front Immunol; 2021; 12():694588. PubMed ID: 34489940
[TBL] [Abstract][Full Text] [Related]
10. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
Gonczol E; Plotkin S
Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
[TBL] [Abstract][Full Text] [Related]
11. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
[TBL] [Abstract][Full Text] [Related]
12. Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses.
Schmitt M; Schmitt A; Wiesneth M; Hückelhoven A; Wu Z; Kuball J; Wang L; Schauwecker P; Hofmann S; Götz M; Michels B; Maccari B; Wuchter P; Eckstein V; Mertens T; Schnitzler P; Döhner H; Ho AD; Bunjes DW; Dreger P; Schrezenmeier H; Greiner J
Theranostics; 2017; 7(6):1705-1718. PubMed ID: 28529646
[No Abstract] [Full Text] [Related]
13. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
Bernstein DI; Munoz FM; Callahan ST; Rupp R; Wootton SH; Edwards KM; Turley CB; Stanberry LR; Patel SM; Mcneal MM; Pichon S; Amegashie C; Bellamy AR
Vaccine; 2016 Jan; 34(3):313-9. PubMed ID: 26657184
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.
Bernstein DI; Reap EA; Katen K; Watson A; Smith K; Norberg P; Olmsted RA; Hoeper A; Morris J; Negri S; Maughan MF; Chulay JD
Vaccine; 2009 Dec; 28(2):484-93. PubMed ID: 19857446
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
Adler SP; Lewis N; Conlon A; Christiansen MP; Al-Ibrahim M; Rupp R; Fu TM; Bautista O; Tang H; Wang D; Fisher A; Culp T; Das R; Beck K; Tamms G; Musey L;
J Infect Dis; 2019 Jul; 220(3):411-419. PubMed ID: 31535143
[TBL] [Abstract][Full Text] [Related]
17. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.
Wloch MK; Smith LR; Boutsaboualoy S; Reyes L; Han C; Kehler J; Smith HD; Selk L; Nakamura R; Brown JM; Marbury T; Wald A; Rolland A; Kaslow D; Evans T; Boeckh M
J Infect Dis; 2008 Jun; 197(12):1634-42. PubMed ID: 18444883
[TBL] [Abstract][Full Text] [Related]
19. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus.
Dasari V; Smith C; Zhong J; Scott G; Rawlinson W; Khanna R
J Gen Virol; 2011 May; 92(Pt 5):1021-1031. PubMed ID: 21307228
[TBL] [Abstract][Full Text] [Related]
20. Vaccines for cytomegalovirus.
Bernstein DI
Infect Disord Drug Targets; 2011 Oct; 11(5):514-25. PubMed ID: 22309618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
